-->

Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer

August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction (GEJ) cancer who have received neoadjuvant chemoradiotherapy and have persistent pathologic disease.

Efficacy was assessed in 794 patients with totally resected (negative margins) esophageal or GEJ malignancies who had residual pathologic disease after concomitant chemoradiotherapy in the CHECKMATE-577 (NCT02743494) randomised, multicenter, double-blind trial. Patients were randomly assigned (2:1) to receive 240 mg of nivolumab or placebo every two weeks for 16 weeks, then 480 mg of nivolumab or placebo every four weeks starting at week 17 for up to one year of treatment.

Disease-free survival (DFS) was the primary efficacy outcome measure. It was defined as the time between randomization and the first recurrence (local, regional, or distant from the primary resected site) date, or death, from any cause, as determined by the investigator prior to subsequent anti-cancer therapy.

In CHECKMATE-577, those who received nivolumab had a statistically significant improvement in DFS when compared to those who received placebo. The median DFS was 22.4 months (95 percent confidence interval: 16.6, 34.0) versus 11 months (95 percent confidence interval: 8.3, 14.3) (HR 0.69; 95 percent confidence interval: 0.56, 0.85; p=0.0003). Regardless of tumour PD-L1 expression or histology, the DFS advantage was seen.

Fatigue, rash, musculoskeletal pain, pruritus, diarrhoea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting are the most common adverse reactions (incidence 20%) in patients receiving nivolumab.

For adjuvant therapy of resected esophageal or GEJ cancer, the recommended nivolumab dose is 240 mg every 2 weeks or 480 mg every 4 weeks for a total treatment duration of 1 year. Both doses are given as intravenous infusions lasting 30 minutes.

 

Reference: https://www.fda.gov/

Check details here.

Take second opinion on esophageal cancer treatment


Send Details

Susan Hau
Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • August 25th, 2021

Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer

Previous Post:
nxt-post

Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer

Next Post:
Tags:
,

Scan the code